LMR Partners’s BioCryst Pharmaceuticals BCRX Stock Holding History

LMR Partners’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-42,400	Closed	-$689K	–	1293
2022 Q1	$689K	Sell	42,400 -70,000	-62%	-$1.12M	0.01%	928
2021 Q4	$1.56M	Buy	112,400 +63,400	+129%	+$839K	0.02%	553
2021 Q3	$704K	Buy	+49,000	New	+$773K	0.01%	721

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LMR Partners's BCRX Position: Q2 2022 in Review

LMR Partners sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2022, closing a stake of 42,400 shares — an estimated $689K sold.

LMR Partners first reported a position in BCRX in Q3 2021 and held it in 3 quarters. The position peaked at $1.56M in Q4 2021. 221 funds tracked by Wall St. Rank hold BCRX as of Q2 2022.

LMR Partners reported no remaining BioCryst Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
LMR Partners sold 42,400 BioCryst Pharmaceuticals shares in Q2 2022, an estimated $689K.
LMR Partners first reported a position in BioCryst Pharmaceuticals in Q3 2021 and held it in 3 quarters.
LMR Partners's BioCryst Pharmaceuticals position peaked at $1.56M in Q4 2021.
221 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2022.

Based on LMR Partners's 13F filing for Q2 2022, filed 15 Aug 2022.